Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Inhaled aprotinin found to reduce viral load in mild-to-moderate COVID-19

Inhaled aprotinin found to reduce viral load in mild-to-moderate COVID-19

What is the viral rebound in untreated COVID-19 infections?

What is the viral rebound in untreated COVID-19 infections?

To what extent did the COVID-19 booster strategy prevent infections and hospitalizations in US adults?

To what extent did the COVID-19 booster strategy prevent infections and hospitalizations in US adults?

Everything you need to know about Paxlovid — especially, should you take it?

Everything you need to know about Paxlovid — especially, should you take it?

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Should siRNA-based antivirals be added to the COVID toolbox?

Should siRNA-based antivirals be added to the COVID toolbox?

Paxlovid resistance associated with SARS-CoV-2 3CLpro mutations

Paxlovid resistance associated with SARS-CoV-2 3CLpro mutations

SARS-CoV-2 can evade Paxlovid by multiple mechanisms

SARS-CoV-2 can evade Paxlovid by multiple mechanisms

SARS-CoV-2 3CLpro also susceptible to mutations

SARS-CoV-2 3CLpro also susceptible to mutations

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Paxlovid is shown to be effective in treating COVID-19

Paxlovid is shown to be effective in treating COVID-19

Insufficient drug exposure most likely to cause COVID-19 rebound

Insufficient drug exposure most likely to cause COVID-19 rebound

Real-world study shows Paxlovid associated with lower hospitalization rates

Real-world study shows Paxlovid associated with lower hospitalization rates

Tracking the emergence of potential drug-resistant mutations in SARS-CoV-2 proteins

Tracking the emergence of potential drug-resistant mutations in SARS-CoV-2 proteins

Prevalence of SARS-CoV-2 infection during Omicron BA.2/BA.2.12.1 surge in New York

Prevalence of SARS-CoV-2 infection during Omicron BA.2/BA.2.12.1 surge in New York

The effectiveness of molnupiravir and nirmatrelvir/ritonavir in reducing hospitalization and deaths in non-hospitalized COVID-19 patients

The effectiveness of molnupiravir and nirmatrelvir/ritonavir in reducing hospitalization and deaths in non-hospitalized COVID-19 patients

Insilico Medicine nominates novel preclinical candidate targeting 3CL protease for COVID-19 treatment

Insilico Medicine nominates novel preclinical candidate targeting 3CL protease for COVID-19 treatment

Efficacy study of Paxlovid and Molnupiravir in real-world settings shows positive results

Efficacy study of Paxlovid and Molnupiravir in real-world settings shows positive results

Evaluating efficacy of SARS-CoV-2 antivirals in a mouse model

Evaluating efficacy of SARS-CoV-2 antivirals in a mouse model

Researchers explore COVID-19 vaccination in immunocompromised individuals

Researchers explore COVID-19 vaccination in immunocompromised individuals